Cargando…
Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer
Background: Prostate cancer (PCa) is the leading cause of death in men and has poor therapeutic outcomes. Methods: A novel endostatin 33 peptide was synthesized by adding a specific QRD sequence on the basis of the endostatin 30 peptide (PEP06) with antitumor activity. Then, bioinformatic analysis a...
Autores principales: | Liu, Yang, Wang, Chang-Lin, Pang, Zhong-Qi, Gao, Ke, Shen, Lin-Kun, Xu, Wan-Hai, Ren, Ming-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003382/ https://www.ncbi.nlm.nih.gov/pubmed/36902648 http://dx.doi.org/10.3390/jcm12051861 |
Ejemplares similares
-
In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma
por: Xie, Fang, et al.
Publicado: (2017) -
Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model
por: Ding, Rui-Lin, et al.
Publicado: (2017) -
Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma
por: Yan, Ma, et al.
Publicado: (2017) -
β-Hydroxyisovaleryl-Shikonin Exerts an Antitumor Effect on Pancreatic Cancer Through the PI3K/AKT Signaling Pathway
por: Zeng, Yu, et al.
Publicado: (2022) -
Endostatin in the pancreas
por: Wigmore, S J
Publicado: (2005)